The US Food and Drug Administration (FDA) has approved Boston Scientific’s Promus Element plus everolimus-eluting platinum chromium coronary stent system.

The Promus Element stent is used to treat patients with coronary artery disease.

The stent system incorporates a low-profile delivery system with a dual-layer balloon and bi-segment inner lumen catheter to provide precise stent delivery across challenging lesions.

The company claims that the everolimus drug and fluorinated copolymer stent coating, which have been studied in multiple randomised clinical trials, showed long-term safety and efficacy.